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Clostridium difficile is a leading cause of antibiotic-associated diarrhea and the etiologic agent responsible for C. difficile infec-
tion. Toxin A (TcdA) and toxin B (TcdB) are nearly indispensable virulence factors for Clostridium difficile pathogenesis. Given
the toxin-centric mechanism by which C. difficile pathogenesis occurs, the selective sequestration with neutralization of TcdA
and TcdB by nonantibiotic agents represents a novel mode of action to prevent or treat C. difficile-associated disease. In this pre-
clinical study, we used quantitative enzyme immunoassays to determine the extent by which a novel drug, calcium aluminosili-
cate uniform particle size nonswelling M-1 (CAS UPSNM-1), is capable of sequestering TcdA and TcdB in vitro. The following
major findings were derived from the present study. First, we show that CAS UPSNM-1 efficiently sequestered both TcdA and
TcdB to undetectable levels. Second, we show that CAS UPSNM-1’s affinity for TcdA is greater than its affinity for TcdB. Last, we
show that CAS UPSNM-1 exhibited limited binding affinity for nontarget proteins. Taken together, these results suggest that
ingestion of calcium aluminosilicate might protect gastrointestinal tissues from antibiotic- or chemotherapy-induced C. difficile
infection by neutralizing the cytotoxic and proinflammatory effects of luminal TcdA and TcdB.
Clostridium difficile is a leading cause of antibiotic-associateddiarrhea (AAD) and is the etiologic agent responsible for C.
difficile-associated infection (CDI). CDI typically starts as a mild
diarrhea but rapidly degenerates into a variety of potentially life-
threatening conditions, including sepsis syndrome and pseu-
domembranous colitis (1). In the United States, approximately
330,000 cases of CDI are estimated to occur each year (2); how-
ever, the incidence ofC. difficile infection continues to increase (2,
3). The increasing CDI rates highlight the fact that the current
infection control procedures and treatment options are insuffi-
cient.
In the health care setting, C. difficile endospores are transmit-
ted to patients via the fecal-oral route (4). Following exposure, the
host’s gastrointestinal microbiota typically either quells a nascent
C. difficile infection or suppresses it to subclinical levels (5). As a
result of the latter, approximately 20% of hospitalized adults be-
come asymptomatic C. difficile carriers, and the carriage rates ap-
proach 50% for patients in long-term care (6–9). The likelihood of
development of CDI increases in patients with dysbiotic gastroin-
testinal microbiota, since C. difficile can thrive in the dysbiotic
niche (5, 10). This dysbiosis is often the result of nonspecific che-
motherapies that are used to treat conditions unrelated to C. dif-
ficile infection (e.g., antibacterial agents or antineoplastic drugs).
The antibiotics metronidazole and vancomycin are currently
used to treat CDI (11). Unfortunately, given the conflicting roles
of antibiotics in the establishment and resolution of CDI, C. diffi-
cile AAD recurs in up to 1 in 5 patients (12). These already high
reoccurrence rates are expected to increase if C. difficile strains
with intermediate and complete resistance to metronidazole and
vancomycin emerge (13). Taken together, these alarming trends
illustrate an urgent need for the development of novel and effica-
cious therapies to treat CDI, including nontraditional therapeutic
agents.
C. difficile is an extracellular pathogen, and it typically does not
invade host tissues. While a number of C. difficile-encoded viru-
lence factors are responsible forC. difficile carriage and pathogen-
esis, toxin A (TcdA) and toxin B (TcdB) are among the best stud-
ied (14). Once secreted into the colon, these cytotoxic protein-
based enzymes are translocated across the membrane bilayer and
into the cytosol by receptor-mediated endocytosis (15). Once in-
side the cell, these glycosyltransferases trigger altered cellular tran-
scription, which results in significant cellular apoptosis and tissue
remodeling (16–18). TcdA and TcdB are also strongly proinflam-
matory, which exacerbates their effects on structural and func-
tional changes in tissue integrity (19, 20). Together, these inflam-
mation-related activities contribute to the progressive ablation of
gastrointestinal function that is characteristic of CDI. In animal
models, the administration of purified C. difficile TcdA induces
the hallmark symptoms of an acute, pseudomembranous colitis-
like condition: edema, gastrointestinal inflammation, cellular ne-
crosis, and gastroenteritis in the absence of the bacterium (19,
21–23). The administration of TcdB elicits similar effects, albeit to
a lesser degree (22, 24). As a result, these protein-based enzymes
have been ascribed as nearly indispensable determinants for C.
difficile pathogenesis.
Given the toxin-centricmechanism bywhichC. difficile patho-
genesis occurs, the selective sequestration with neutralization of
TcdA and TcdB by nonantibiotic agents represents a novel mode
of action to prevent or treatC. difficile-associated diseases (25, 26).
To date, four C. difficile toxin-binding agents (i.e., cholesty-
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ramine, colestipol, Synsorb 90, and tolevamer) have been exam-
ined in preclinical studies (25). Of these toxin-binding agents,
only three have been tested in clinical studies. Unfortunately,
none of these agents has proven to be as efficacious as traditional
antibiotic therapies. Nevertheless, it is important to continue to
develop new candidate therapies. In this article, we describe the
characterization of calcium aluminosilicate uniform particle size
nonswelling M-1 (CAS UPSNM-1), a novel calcium aluminosili-
cate agent that has been developed to selectively bind to and neu-
tralize large clostridial protein toxins. Calcium aluminosilicate is
recognized by the Food andDrug Administration (FDA) as a gen-
erally regarded as safe (GRAS) additive, which can be used as a
supplement to foods at levels up to 2% (wt/wt) (27).
MATERIALS AND METHODS
Protein-based cytotoxic enzymes and reagents. Lyophilized C. difficile
TcdA and C. difficile TcdB were stored according to the manufacturer’s
specifications (Calbiochem, Gibbstown, NJ). TcdA and TcdB were resus-
pended in 10 mM 2,2-bis(hydroxymethyl)-2,2=,2-nitrilotriethanol (bis-
Tris) buffer (Sigma-Aldrich, St. Louis, MO) and maintained on ice prior
to being assayed. All other chemicals were molecular biology grade and
stored as recommended by the manufacturer. A SevenMulti conductivity
meter (Mettler Toledo, Columbus, OH) was used for pH measurements.
Putative toxin-binding agent. Calcium aluminosilicate uniform par-
ticle size nonswellingM-1 (CASUPSNM-1), the novel sequestering agent
used in this study, was provided by Salient Pharmaceuticals Incorporated
(Houston, TX).
Quantitative enzyme immunoassay for toxin quantification. The
concentration of C. difficile TcdA or TcdB was measured using the Pre-
mier Toxins A&B enzyme immunoassay (EIA) according to themanufac-
turer’s instructions (Meridian Bioscience, Inc., Cincinnati, OH), except
that a series of assay positive-control samples (i.e., TcdA and TcdB refer-
ence standards at a range of known concentrations) was incorporated into
each repeated measurement; the concentrations of these reference stan-
dards typically ranged from 5 to 20 ng/ml. In brief, the resultant quanti-
tative enzyme immunoassay (qEIA) uses C. difficile TcdA- and TcdB-
specific polyclonal antibodies to capture TcdA and TcdB and to
noncovalently anchor them to the solid-phase EIA support matrix. The
matrix-bound toxins were subsequently complexedwith horseradish per-
oxidase (HRP)-conjugated mouse anti-toxin A (monoclonal) or goat
anti-toxin B (polyclonal) antibodies, respectively. After the removal of the
unbound HRP-antibody conjugates, the degradation of urea hydrogen
peroxide by toxin-bound horseradish peroxidase was assayed in the pres-
ence of the reducing cosubstrate 3,3=,5,5=-tetramethyl-(1,1=-biphenyl)-
4,4=-diamine (TMB). Phosphoric acid (1 M) was used to arrest the reac-
tion. The terminal chromophore benzidine-4,4=-diimine (BZDI), an
oxidized derivative of TMB, was measured in arbitrary units (AU) at an
optical density of 450 nm (OD450) using an Infinite M200 microplate
reader (Tecan US, Inc., Durham, NC). Infinite M200 i-Control software
was used to generate custom EIA microplate templates to speed data ac-
quisition and to ensure accurate sample assignation.
Toxin sequestration assays. This qEIA was used to assess the seques-
tration (an aggregate of adsorption and absorption) of large clostridial
protein toxins by calcium aluminosilicate. Unless otherwise indicated,
calcium aluminosilicate was suspended up to a final concentration of 0.5
mg/ml in 10mMbis-Tris (pH 6.5) and preequilibrated to 37°C in a Ther-
momixer R shaking incubator (Eppendorf, Hauppauge, NY) equipped
with a 1.5-ml block with constant agitation at 1,200 rpm. The individual
sequestration reactions were started by the addition of the toxin to a final
concentration of 10 ng/ml (TcdA) or 15 ng/ml (TcdB), unless otherwise
indicated. Sequestration reaction mixtures were then incubated for 10
min at 37°C with constant agitation at 1,200 rpm in a Thermomixer R.
The sequestration reaction was stopped when the residual calcium alumi-
nosilicate and calcium aluminosilicate-bound toxin complexes were pel-
leted by centrifugation (2 min at 21,130 g) in a 5424 benchtop centri-
fuge (Eppendorf). Following centrifugation, the clarified supernatant was
carefully removed by aspiration, transferred to a 1.5-ml tube, and chilled
on ice prior to toxin quantification using the qEIA described above.
Heterologous, nontarget protein binding and SDS-PAGE. Calcium
aluminosilicate (5 mg/ml) was coincubated with the SeeBlue Plus2 pro-
tein ladder (750 g/ml; Invitrogen, San Diego, CA), which contains a
number of nontarget proteins. Samples were incubated at 37°C for 20min
with constant agitation (1,200 rpm). The reaction was stopped when the
residual calcium aluminosilicate and calcium aluminosilicate-bound pro-
tein complexes were pelleted by centrifugation (2min at 21,130 g) in an
Eppendorf 5424 benchtop centrifuge. The supernatant was carefully
transferred to a fresh tube and set on ice. The pellet containing the residual
calcium aluminosilicate and calcium aluminosilicate-bound protein
complexes was resuspended in 1 volume of buffer and agitated for 20min
(1,200 rpm). The unbound calcium aluminosilicate and calcium alumi-
nosilicate-bound protein complexes were again pelleted by centrifugation
(2 min at 21,130 g). The resultant pellet eluate, including any proteins
eluted from the calcium aluminosilicate, was carefully transferred to a
fresh tube. Negative-control samples (i.e., SeeBlue Plus2 devoid of cal-
cium aluminosilicate) were otherwise treated identically to the experi-
mental samples.
The original supernatant and the pellet eluatewere subjected to PAGE.
Samples (15 l) were loaded into the 1-mm wells of a NuPAGE Novex
Tris-acetate gel (Invitrogen) using 1 lithiumdodecyl sulfate (LDS) sam-
ple buffer (Invitrogen). The protein electrophoresis was carried out (150
V for 1 h) in an Xcell SureLock mini cell (Invitrogen) and 1 NuPAGE
Tris-acetate SDS running buffer (Invitrogen). Proteins were stained using
the SimplyBlue SafeStain (Invitrogen), according to the manufacturer’s
instruction. The results were captured using the FluorChem HD2 docu-
mentation system with a 5-MHz cooled digital charge-coupled-device
camera (Alpha Innotech).
Biostatistics. Raw qEIA data were captured using Infinite M200 i-
Control software, exported to Excel (Microsoft Corporation, Redmond,
WA), and analyzed using Prism (GraphPad Software, Inc., La Jolla, CA).
Unless otherwise indicated, the data represent at least three repeatedmea-
sures. The data are expressed as the mean (x) either the standard error
of the mean (SEM) or the standard deviation (SD), as noted. Calibration
curves were generated by least-squares regression. Analysis of variance
(ANOVA) was used to determine the statistical significance of the mea-
sured differences between treatments. When significant differences were
detected by ANOVA, Bonferroni tests were performed post hoc in order to
explore these differences. An associated P value of0.05 was considered
statistically significant. The base 10 logarithm (log10) of each data point
was calculated, and a calibration curve for the interpolation of unknowns
was generated using least-squares linear regression.
RESULTS
Optimization of a qEIA to detect TcdA and TcdB. Samples con-
taining known concentrations of TcdA or TcdB were used to gen-
erate standard curves. The standard curves from each of six ran-
domly selected vials of TcdB are plotted in Fig. 1. A one-factor
ANOVA found that toxin vial-specific effects were statistically sig-
nificant (P  0.0051); however, post hoc comparisons using the
Bonferroni test indicated that, with the exception of one obvious
outlier (P  0.05), the differences between the remaining five
curves were statistically nonsignificant (P 0.05). For this exper-
imental subset (n 5), the Pearson product-moment correlation
coefficient (r) indicated a strong, colinear relationship between
the toxin concentration and optical density that was statistically
significant between interexperimental EIA replicates (r 0.9078,
P 0.0047). Similar results were seen for TcdA (n 5), although
the differences between the individual vials of TcdA were statisti-
cally nonsignificant (P  0.8707). As seen with TcdB, a strong
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colinear relationship between the toxin concentration and optical
density was observed. This colinear relationship was statistically
significant between interexperimental qEIA replicates (r 
0.9973, P  0.0027). In separate experiments that examined the
effect of toxin thermostability, the differences in the qEIA reactiv-
ity following short-term (e.g., 8 h) incubation on icewere found to
be statistically nonsignificant (P  0.05). As a result, individual
toxin vials were used to conduct multiple sequestration assays
within a single workday and were then discarded.
Data distribution and transformation. The descriptive statis-
tic skewness (g1) and the Kolmogorov-Smirnov (K-S) normality
test were used to examine the data distribution within the TcdA
and TcdB data sets.While both data sets skewed right (TcdA, g1
0.6626; TcdB, g1 1.331), the K-S test indicated that neither ex-
hibited significant differences from the Gaussian distribution
(P  0.10). Nevertheless, the log10 of each data point was calcu-
lated to normalize the data. The linear regressions of the mean
TcdA (n 4; R2 0.968) and TcdB (n 5; R2 0.966) reference
curves are plotted in Fig. 2. Signal response plateauswere observed
at very high toxin concentrations and very low toxin concentra-
tions (data not shown).
Calcium aluminosilicate does not affect the pH of the qEIA
system. In order to determine if calcium aluminosilicate might
artificially diminish the sensitivity of the qEIA by affecting the pH
of the buffer system, calciumaluminosilicatewas supplemented to
a final working concentration of 0.5 mg/ml in 100 mM Tris (pH
6.5), and the pH was measured (n  3) once the mixture was
equilibrated to 37°C. The incorporation of calcium aluminosili-
cate up to 0.5 mg/ml did not affect the pH of the buffer system (x,
6.52; SD, 0.01) compared to that of a buffer control that was de-
void of calcium aluminosilicate (x, 6.50; SD, 0.001), as expected.
Effective, dose-dependent sequestration of large C. difficile
cytotoxic enzymes by calcium aluminosilicate. Calcium alumi-
nosilicate was assessed for its ability to reduce the concentration of
large clostridial protein-based cytotoxic enzymes in vitro. During
these dose-response experiments, the concentration of TcdA or
TcdB (Fig. 3) was fixed at 10 ng/ml, while the calcium alumino-
silicate concentration was varied 100-fold (i.e., 0.05 mg/ml, 0.075
mg/ml, 0.1 mg/ml, 0.3 mg/ml, 0.5 mg/ml, 0.75 mg/ml, 1 mg/ml, 2
mg/ml, 3 mg/ml, and 5 mg/ml). Calcium aluminosilicate effi-
ciently sequestered TcdA and TcdB in vitro. The differences in the
mean endpoint OD450 values between the assay negative-control
(i.e., vehicle devoid of TcdA) samples (x, 0.044 AU; SD, 0.001 AU)
and the experimental samples supplemented with calcium alumi-
nosilicate up to 2mg/ml (x, 0.049 AU; SD, 0.004 AU), 3mg/ml (x,
0.049 AU; SD, 0.005 AU), and 5 mg/ml (x, 0.048 AU; SD, 0.004
AU) were statistically nonsignificant (P 0.05).
The raw qEIA measurements obtained from the experimental
samples were converted to residual toxin concentrations using the
intraexperimental EIA calibration curves. The differences in the
residual TcdA concentrations between the assay positive-control
(i.e., TcdA-containing samples devoid of calciumaluminosilicate)
samples and the experimental samples containing calcium alumi-
nosilicate supplemented up to 0.05 mg/ml (x, 11.11 ng/ml; SD,
1.82 ng/ml), 0.075 mg/ml (x, 11.35 ng/ml; SD, 0.22 ng/ml), and
0.1 mg/ml (x, 10.93 ng/ml; SD, 0.06 ng/ml) were statistically non-
significant (Fig. 3). In contrast, statistically significant differences
in the residual TcdA concentrations were measured between the
assay positive-control and experimental samples containing cal-
cium aluminosilicate supplemented to 0.3 mg/ml (x, 8.54 ng/ml;
FIG 1 Untransformed EIA calibration curves. The mean optical density (y
axis) for each of six randomly selected cytotoxin B EIA calibration curves is
plotted as a function of the cytotoxin B concentration (x axis). The data are
expressed as means SEM.
FIG 2 Linear regression of representative logarithm-transformed qEIA cali-
bration data. The logarithm (base 10) of the optical density of each reference
standard (y axis) was determined by EIA and plotted against the toxin concen-
tration (x axis). Circles denote the median calibration data from n repeated
replicates. The solid line denotes the linear regression with 95% confidence
limits, and the dashed lines denote the boundaries of the calculated 95% con-
fidence interval. (A) Linear regression of enterotoxin A data (n  5, R2 
0.968). (B) Linear regression of cytotoxin B calibration data (n  4, R2 
0.966).
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SD, 1.19 ng/ml; P  0.05), 0.5 mg/ml (x, 4.88 ng/ml; SD, 0.80
ng/ml; P 0.001), 0.75mg/ml (x, 3.20 ng/ml; SD, 0.65 ng/ml; P
0.001), 1mg/ml (x, 1.67 ng/ml; SD, 0.71 ng/ml), 2mg/ml (x, below
the lower limit of detection [bLLD]; P  0.001), 3 mg/ml (x,
bLLD; P 0.001), and 5 mg/ml (x, bLLD; P 0.001). The lower
limits of detection for this qEIA are approximately 1.4 ng/ml for
TcdA and 2.4 ng/ml for TcdB.
The efficiency by which the calcium aluminosilicate seques-
tered TcdB was also explored (Fig. 3). The differences in endpoint
OD450 measurements between the assay negative-control (i.e., ve-
hicle devoid of TcdB) samples (x, 0.047AU; SD, 0.004AU) and the
experimental samples supplementedwith calciumaluminosilicate
up to 3 mg/ml (x, 0.043 AU; SD, 0.001 AU) and 5mg/ml (x, 0.041
AU; SD, 0.002 AU) were statistically nonsignificant (P 0.05). As
performed with TcdA, the raw qEIA measurements were con-
verted to residual toxin concentrations. The differences in the re-
sidual TcdB concentrations between the assay positive-control
(i.e., TcdB-containing samples devoid of calcium aluminosilicate)
samples and the experimental samples containing calcium alumi-
nosilicate supplemented up to 0.05mg/ml (x, 9.07 ng/ml; SD, 0.06
ng/ml), 0.075 mg/ml (x, 8.75 ng/ml; SD, 0.05 ng/ml), 0.1 mg/ml
(x, 9.02 ng/ml; SD, 1.38 ng/ml), and 0.3mg/ml (x, 8.44 ng/ml; SD,
0.8 ng/ml) were statistically nonsignificant (P 0.05). In contrast,
statistically significant differences in residual TcdB concentrations
were measured between the assay positive-control and the exper-
imental samples containing calcium aluminosilicate supple-
mented up to 0.5 mg/ml (x, 6.27 ng/ml; SD, 0.36 ng/ml; P 
0.001), 0.75 mg/ml (x, 5.47 ng/ml; SD, 0.64 ng/ml; P 0.001), 1
mg/ml (x, 4.99 ng/ml; SD, 1.23 ng/ml;P 0.001), 2mg/ml (x, 3.75
ng/ml; P 0.001), 3mg/ml (x, bLLD; P 0.001), and 5mg/ml (x,
bLLD; P 0.001).
Protein-binding activity of calcium aluminosilicate. The se-
lectivity of calcium aluminosilicate’s protein-binding activity was
explored further using a variation of the C. difficile toxin-binding
assay described above. During these experiments, calcium alumi-
nosilicate (5 mg/ml) was challenged with a commercial protein
cocktail that contained a number of nontarget proteins, including
myosin, bovine serum albumin, and glutamate dehydrogenase.
Representative SDS-PAGE gels of the supernatant and the pellet
eluate can be found in Fig. 4. CAS UPSN M-1 bound nontarget
proteins but did so with various efficiencies. Indeed, CAS UPSN
M-1 boundmyosin and bovine serum albumin inefficiently, while
glutamate dehydrogenase was bound efficiently. Attempts to elute
proteins bound toCASUPSNM-1were unsuccessful (Fig. 4, lanes
4 and 5), which suggests that proteins bound to CAS UPSN M-1
are bound tightly.
FIG 3 Selective and dose-dependent adsorption of C. difficile toxins by CAS UPSN M-1 in vitro. CAS UPSN M-1 was supplemented to a final concentration
between 0.05 and 5 mg/ml (100-fold range) (x axis), while the toxin concentration was fixed to 10 g/ml (dashed line). After a 10-min coincubation, the
mineral-toxin complexes were removed by centrifugation, and the residual concentrations of enterotoxin A (blue) and cytotoxin B (red) were determined by
quantitative EIA (y axis). The data are expressed as the means SD. The statistical significance of the differences in the toxin-specific binding ability is reported
for each concentration. ns, statistically nonsignificant (P 0.05); **, statistically significant (P 0.01); ***, statistically significant (P 0.001).
FIG 4 Nontherapeutic protein-binding assay. SDS-PAGE gels illustrating dif-
ferential binding ofmyosin (top panel), bovine serum albumin (BSA) (middle
panel), and glutamate dehydrogenase (GLUD) (bottom panel). Lane 1, un-
treated reference protein (negative control); lanes 2 and 3, CAS UPSN M-1-
treated protein samples (duplicates); lanes 4 and 5, eluates of protein-bound-
CAS UPSN M-1 complexes (duplicates). White carets mark the lanes that are
devoid of a protein band.
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DISCUSSION
The initial toxin concentrations used in this study were selected
because they approximated the median concentration of TcdA
(4.3 ng/ml) that is typically found in the stools of patients with C.
difficile-associated diarrhea (range, 0.6 ng/ml to 19 g/ml) (28).
As such, the qEIA protocol developed in this study enabled C.
difficile TcdA and TcdB quantification at clinically relevant con-
centrations. No hook effect was obvious for either toxin at toxin
concentrations between 5 and 15 ng/ml, which constituted the
linear range for this qEIA. The high-dose hook effect occurs when
the antigen negatively affects the binding capacity of the reporter
antibody or when it is added in excess of the reporter antibody
(29). The intraexperimental EIA calibration curves generated us-
ing this qEIA protocol enabled toxin quantification via interpola-
tion and, thus, facilitated the conversion of optical density mea-
surements to residual toxin concentrations. Furthermore, given
the high degree of reproducibility, this qEIA supported interex-
perimental comparisons between repeated measurements (e.g.,
randomized block experiments).
This assay revealed that calcium aluminosilicate efficiently re-
moved both TcdA and TcdB at physiologically relevant concen-
trations. Indeed, calcium aluminosilicate neutralized TcdA to
subclinical levels in vitro. As for tolevamer, protein binding by
calcium aluminosilicate does not occur in a generalized or other-
wise indiscriminate fashion and, thus, displays a degree of target
specificity. Tolevamer is an anionic, high-molecular-weight poly-
mer (400 kDa) that was developed to neutralize TcdA andTcdB.
Tolevamer has been shown to ameliorate CDI-like symptoms in
hamsters (30). In addition, tolevamer has demonstrated thera-
peutic efficacy in a number of phase II and phase III clinical stud-
ies (25, 26). While effective, tolevamer’s cure rate was found to be
inferior to those of vancomycin and metronidazole (26, 31). Sur-
prisingly, however, the rate of CDI reoccurrence was generally
lower with tolevamer than with either vancomycin or metronida-
zole (26).
TcdA and TcdB are postulated to be paralogs (32, 33). As a
result, these proteins share significant amino acid sequence simi-
larity to one another, especially at their amino- and carboxy-ter-
minal regions. The two toxins share approximately 47% identity
to each other and approximately 68% sequence similarity (data
not shown). Both proteins are composed of three well-character-
ized functional domains (15). The amino terminus of the protein
encodes a peptidase C80-type glycosyltransferase domain and a
proximal substrate recognition domain. The hydrophobic middle
region is putatively involved inmembrane translocation. The car-
boxy terminus of the protein encodes the clostridial repetitive
oligopeptides (CROPS) (also known as cell wall-binding [CWB]
domains). The carboxy-terminal CROPS facilitate calcium-de-
pendent host cell recognition (33) and may also play a role in the
sequestration of TcdA and TcdB by calcium aluminosilicate. Pro-
teins that are evolutionarily and/or structurally related to TcdA
and TcdB might also be viable therapeutic targets for calcium
aluminosilicate; however, additional research is required to test
this hypothesis.
In addition to the similarities noted above, a number of toxin-
specific differences were also observed. For example, the lowest
experimental concentration of calcium aluminosilicate for which
there was no observable effect was 0.1 mg/ml for TcdA but 0.3
mg/ml for TcdB. The minimum effective concentration (i.e., the
threshold dose) for calcium aluminosilicate was 0.3 mg/ml for
TcdA but 0.5 mg/ml for TcdB. Under these conditions, the cal-
cium aluminosilicate concentration that achieved the maximum
efficacy (EC100) was 2 mg/ml for TcdA, but the concentration of
calcium aluminosilicate that provided approximately 50% of the
maximum effect (EC50) for TcdA was 0.5 mg/ml. In contrast, the
EC100 and EC50 for TcdB were 3mg/ml and 1mg/ml, respectively.
While calcium aluminosilicate sequesters both protein-based cy-
totoxic enzymes, these results suggest that its affinity for TcdA is
greater than its affinity for TcdB.
As antibiotic-resistant pathogens continue to emerge, the de-
velopment of nonantibiotic treatment options represents a timely
therapeutic approach to CDI management. Calcium aluminosili-
cate exhibited potent C. difficile TcdA- and TcdB-neutralizing ac-
tivity and selective protein binding in vitro. Given the well-docu-
mented safety profile of calcium aluminosilicate (34), these
studies provide in vitro evidentiary support of our hypothesis that
ingestion of calcium aluminosilicate might protect gastrointesti-
nal tissues and accelerate a patient’s recovery from antibiotic- or
chemotherapy-inducedC. difficile-associated diarrhea by neutral-
izing the cytotoxic effects of luminal TcdA and TcdB. Depending
on its relative effectiveness and tolerability during downstream
clinical studies, CAS UPSN M-1, the novel sequestration agent
described in this study, may be used to complement or, possibly,
replace existing antibiotic therapies for the treatment of CDI.
However, it is beyond the scope of this current study to examine
the biological effects of calcium aluminosilicate in vivo.
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